Načítá se...
Eligibility and Preventive Potential for New Evidence-Based Cardiovascular Drugs in Secondary Prevention
IMPORTANCE: Recently, 12 randomized clinical trials (RCTs) have demonstrated the efficacy of novel therapies for mainly secondary prevention of atherosclerotic cardiovascular disease. However, given the potential overlapping eligibility of the RCTs, along with the cost of the new therapies, there ar...
Uloženo v:
| Vydáno v: | JAMA Cardiol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Medical Association
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6990962/ https://ncbi.nlm.nih.gov/pubmed/31895459 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2019.4759 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|